BioSpace News Archive

Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, announced that Weston Miller, M.D., will join the company as chief medical officer effective October 23, 2023.

IDEAYA Biosciences, Inc. announces the publication of the abstract for a proffered paper session at the European Society of Medical Oncology Congress 2023 relating to selected clinical data from the company’s ongoing Phase 2 clinical trial evaluating darovasertib in combination with crizotinib in patients having metastatic uveal melanoma.

Merck, known as MSD outside of the United States and Canada, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of PREVYMIS® for prophylaxis of cytomegalovirus disease in adult kidney transplant recipients at high risk.

Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs)

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R) today announced that it has entered into an agreement with Defence R&D Canada - Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, to evaluate Bucillamine as a potential treatment for nerve agent exposure.

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed with BDC-3042 in the single-agent dose-escalation portion of this first-in-human Phase 1/2 clinical study.

Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo” or the “Company”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced top-line results from its Phase 2 clinical study with EDP2939 in moderate psoriasis.

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to evaluate NKX019, its allogeneic, CD19-directed CAR NK cell therapy candidate, for the treatment of lupus nephritis.

Persephone Biosciences Inc. and Ginkgo Bioworks announced the completion of their first collaboration together, a Bacteroides engineering toolkit.

inTRAvent Medical Partners LP, a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve neurosurgical procedures, announced the appointment of Kevin Foley, MD, in the newly created role of Chief Innovation Officer.